Intuitive Surgical Q3 revenue surged 23%, skyrocketing 17% after hours with strong growth in Da Vinci surgeries

According to Zhitong Finance APP, after the market closed on October 21 (Tuesday) Eastern Time, Intuitive Surgical, a global technology leader in minimally invasive care and a pioneer in robotic-assisted surgery (ISRG.US), released its quarterly financial performance for the period ending September 30, 2025. The financial report shows that the company's revenue for the third quarter reached $2.51 billion, an increase of 23% compared to $2.04 billion in the third quarter of 2024; on a GAAP basis, net profit was $704 million, with diluted earnings per share of $1.95, compared to $565 million and $1.56 in the same period last year; non-GAAP net profit was $867 million, with diluted earnings per share of $2.40, compared to $669 million and $1.84 in the same period last year. The revenue growth was mainly driven by an increase in the number of surgeries, an increase in the deployment of the da Vinci surgical system, and an expansion in the installation of equipment. In this quarter, the company deployed 427 da Vinci systems, a significant increase from 379 systems in the same period last year; 50 Ion systems were deployed, compared to 58 in the same period last year. The number of surgeries increased by approximately 20% year-on-year, with da Vinci system surgeries growing by about 19% and Ion system surgeries growing by about 52%. As of the end of the third quarter of 2025, the company's total cash, cash equivalents, and investments amounted to $8.43 billion, a decrease of $1.1 billion from the beginning of the quarter, which was approximately $8.8 billion on December 31, 2024. The decrease was primarily due to cash used for common stock repurchases and capital expenditures, partially offset by cash from operating activities. Additionally, the company repurchased 4 million shares of stock for $1.92 billion. Looking ahead, the company expects a global growth rate of approximately 17% to 17.5% for da Vinci surgical system surgeries in 2025, compared to 17% in 2024; the non-GAAP gross margin is expected to be between 67% and 67.5% of revenue, compared to 69.1% in 2024, with this range including approximately 0.7% revenue impact from tariffs (fluctuating by 10 basis points); the non-GAAP operating expense growth rate is expected to be between 11% and 13%, compared to 10% in 2024. As of the time of publication, Intuitive Surgical's stock rose over 17% in after-hours trading, priced at $543.00